Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06796803 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary endpoints revised (2)
    • Study sites: 1 to 2
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: 6 to 5
  2. Interventions: camerlizumab+apatinib (Drug), camrelizumab combined with apatinib and HAIC (Drug) to camerlizumab + rivoceranib (Drug), camrelizumab combined with rivoceranib and HAIC (Drug)
    • Study description revised
    • Study title expanded, about 1 word
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.
Trial Details
NCT Number NCT06796803
Lead Sponsor Shanghai Zhongshan Hospital
Collaborators: Jiangsu Hengrui Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Potentially Resectable Hepatocellular Carcinoma
Related terms Carcinoma, Hepatocellular
Enrollment 398 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov